SCHEMBL18311606

SCHEMBL18311606

CCOc1ccc(-c2cccc(C(=O)N(C)C)c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.59
▸ HPGD P15428 2/20 0.59
▸ TSHR P16473 1/20 0.59
▸ RXRA P19793 1/20 0.56
▸ RXRB P28702 1/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ ERN1 O75460 1/20 0.52
▸ CYP3A4 P08684 1/20 0.50
▸ MAP4K1 Q92918 1/20 0.50
▸ GFER P55789 1/20 0.49
▸ TP53 P04637 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ NFKB2 Q00653 1/20 0.48
▸ RELA Q04206 1/20 0.48
▸ MRGPRX4 Q96LA9 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26681150 0.85 ALDH1A1 (0.59) LMNAHPGDSMN1; SMN2NPC1RAB9A
SCHEMBL20057645 0.84 HPGD (0.72) LMNAHPGDTSHRSMN1; SMN2NPC1
SCHEMBL5151396 0.84 RXRA (0.60) LMNAHPGDTSHRRXRARXRB
SCHEMBL15183798 0.81 MEN1 (0.62) RXRARXRBSMN1; SMN2NPC1RAB9A
SCHEMBL19567237 0.81 ERN1 (0.56) LMNAHPGDTSHRERN1CYP3A4
SCHEMBL12342918 0.81 CYP3A4 (0.59) CYP3A4MAP4K1
SCHEMBL22551138 0.80 HPGD (0.59) LMNAHPGDTSHRSMN1; SMN2NPC1
SCHEMBL30283775 0.80 ERN1 (0.60) LMNAHPGDTSHRSMN1; SMN2ERN1
SCHEMBL1135975 0.80 ERN1 (0.60) LMNAHPGDTSHRSMN1; SMN2ERN1
SCHEMBL9388919 0.80 ALDH1A1 (0.66) LMNAHPGDSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof UNIVERSITY OF TSUKUBA (JP) 2019-07-16 — — US disclosed
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof UNIVERSITY OF TSUKUBA (JP) 2019-07-16 — — US disclosed
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF UNIVERSITY OF TSUKUBA (JP) 2018-06-28 — — US disclosed
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF UNIVERSITY OF TSUKUBA (JP) 2018-06-28 — — US disclosed
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF UNIVERSITY OF TSUKUBA (JP) 2018-06-28 — — US disclosed
EP-3309146-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF University of Tsukuba (JP) 2018-04-18 — — EP disclosed
WO-2016199906-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF 国立大学法人筑波大学 2016-12-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF HCRTR2, HCRTR1, NPSR1 LMNA 3544/4885HPGD 2993/4885TSHR 424/4885
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof HCRTR2, HCRTR1, NPSR1 LMNA 3544/4885HPGD 2993/4885TSHR 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback